Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Propylene glycol, found in the purest pharma grade for injection, stands out for its trusted place in the pharmaceutical world. Pharmacies, hospitals, and medical companies count on this ingredient because it brings both utility and safety to the table in injectable drugs. Recognized under international standards like BP (British Pharmacopoeia), EP (European Pharmacopoeia), and USP (United States Pharmacopeia), manufacturers know what they’re getting, and so do healthcare professionals. It wins trust through its clarity—propane-1,2-diol, molecular formula C3H8O2, and CAS number 57-55-6. The specific gravity usually sits close to 1.036, with dependable solubility in water or various solvents.
In its pharma grade, propylene glycol shows up as a nearly colorless, viscous liquid free from odor and with barely any taste. You might see it poured into a clear glass, looking like clean, slightly syrupy water. It comes neither in flakes, powder, nor solid or pearl form for injection use—its value as a liquid keeps things simple for mixing with actives or diluents. There are crystal and granular forms outside the pharma world, but not in syringes or vials meant for hospitals. Its consistency matters; the viscosity gives confidence to professionals who need predictable rates during injections or drips. In the lab, its refractive index lands around 1.432—just another way quality is measured. Its chemical structure holds two hydroxyl groups (-OH), making it good at holding, dissolving, and stabilizing medicines that need a friendlier carrier than water alone.
Spec sheets mean something in this business. For pharmaceutical injection, impurities must sit well beneath strict thresholds—no color, no visible particulate, and heavy metals have to fall under 0.5 ppm. Residue on evaporation checks keep out unwanted bits. Acidity and alkalinity land between pH 6 to 8. This level of control keeps patients safe. The HS Code for custom classification runs as 29053200, telling customs, importers, and manufacturers that the barrel or container inside holds the right thing for regulated pharma trade. Quality assurance labs log refractive index, specific gravity, and water content on every new lot. Only material that passes these checks leaves the gate.
Propylene glycol is not a mystery for safety officers in health care. Most patients tolerate it, especially in the low concentrations designed for injectable meds. Studies from peer-reviewed journals, including reviews by the FDA and EMA, show it has low toxicity and leaves the body through natural metabolism. Still, like any chemical raw material, too much or wrong use can bring trouble. High doses may cause hemolysis, kidney strain, or metabolic acidosis, especially in infants or those with kidney issues. That sobering detail shapes how formulations get their propylene glycol amounts tightly monitored—no cutting corners. Labels and material safety data sheets repeat these facts over and over. Global pharmacopeia approvals do not mean it can be tossed in at will. Real professionals rely on these warnings and only approve propylene glycol based on a drug’s careful clinical risk assessment.
Drug developers see propylene glycol as a workhorse. Its molecular structure lets it dissolve and blend both hydrophilic and hydrophobic medications—useful for injectables that water alone can’t hold. Whether formulating a sedative, an anti-seizure drug, or an anticancer agent, propylene glycol does its job, mixing actives without changing their power or purity. In my experience walking through pharmaceutical manufacturing lines, technicians talk of it as a trustworthy raw material. Its batch-to-batch consistency matters every day for compliance. Pharmacists handling it appreciate that cleanup is easier, spills are rarely an emergency, and it doesn't vaporize toxins into the air like some harsher solvents.
Some sectors worry about alternative options to remove rare but real risks, especially for infants or those with known kidney impairment. Regulatory agencies recommend switching to less reactive carriers when possible, especially in pediatric medicine. There’s research into greener solvents, but propylene glycol stays in place on most hospital shelves because alternatives lag behind in transparency and consistency. Solutions for safer use lie in stronger education for nurses, formulators, and hospital pharmacists—knowing when not to use it, reading batch certificate of analysis, and checking the source. Regular quality audits of suppliers can catch contamination or off-spec product. If standards stay high, and nobody relaxes their guard, propylene glycol keeps doing its job for patients who need injectable drugs, and health teams can rely on outcomes rooted in solid science, not marketing promise or wishful thinking.
Chengguan District, Lanzhou, Gansu, China
